Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 11,256 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Newborn Clear all

Conditions: Infant, Newborn, Disease, Genetic Disease
Interventions: Neonate WGS Testing; Diagnostic Test
Lead sponsor: Jerry Vockley, MD, PhD; Other
Eligibility: Up to 1 Year
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Dravet Syndrome, Lennox Gastaut Syndrome
Interventions: ZX008 0.2 to 0.8 mg/kg/day, Cannabidiol; Drug
Lead sponsor: Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Atlanta, Georgia • Tacoma, Washington

Conditions: Breastfeeding, Patient Simulation, High Fidelity Simulation Training
Interventions: Positioning and Attachment video-based simulation (telesimulation); Other
Lead sponsor: LiquidGoldConcept; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Ypsilanti, Michigan

Conditions: Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital, Ocular Hypertension
Interventions: QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2%; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cystic Fibrosis, Liver Disease or Abnormalities, Diabetes, Pancreatic Insufficiency (Exocrine and Endocrine)
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 4 Years to 120 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1988 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lynch Syndrome
Interventions: Electronic Consent (iPad); Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 703 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Warm Autoimmune Hemolytic Anemia
Interventions: ALXN1830, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Riverside, California

Conditions: Neurodevelopmental Disorders, Intellectual Disability, Development Delay, ADHD, Autism Spectrum Disorder, Epilepsy
Interventions: Sulfonylurea; Drug
Lead sponsor: Royal Devon and Exeter NHS Foundation Trust; Other
Eligibility: 2 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency
Interventions: Olipudase alfa; Drug
Lead sponsor: Sanofi; Industry
Eligibility: Up to 2 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Chicago, Illinois • Cincinnati, Ohio • Columbus, Ohio + 3 more

Conditions: Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism, Pseudohypoparathyroidism Type Ia, Albright Hereditary Osteodystrophy
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 6 Years to 50 Years
Enrollment: 14 participants
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hunter Syndrome
Interventions: idursulfase-IT, No IT treatment; Biological · Other
Lead sponsor: Shire; Industry
Eligibility: Up to 18 Years · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Interventional Diet; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Tics, Tourette Disorder, Tourette Syndrome in Children, Tourette Syndrome in Adolescence
Interventions: Habit Reversal Training; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 8 Years to 17 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Posture, Balance, Cerebral Palsy, Autism, Down Syndrome
Interventions: Training with weighted ball; Other
Lead sponsor: University of Hartford; Other
Eligibility: 8 Years to 25 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: West Hartford, Connecticut

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Persistent Fetal Circulation Syndrome, Persistent Pulmonary Hypertension of Newborn
Interventions: Not listed
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 7 Days
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1994
U.S. locations: 13
States / cities: Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more

Conditions: Lactose Intolerants, Lactose Malabsorption, Caseins
Interventions: A1/A2 milk with oral naloxone, A1PF milk with oral naloxone; Other
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
Interventions: Red Cell Transfusions, Iron Chelation, Hydroxyurea, Phlebotomy; Procedure · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 18 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 28
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 23 more

Conditions: Glycogen Storage Disease Type II
Interventions: Not listed
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 8 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • St Louis, Missouri • Seattle, Washington

Conditions: Fabry Disease, Proteinuria
Interventions: enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 5
States / cities: Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 2 more

Conditions: X-linked Hypophosphatemia
Interventions: KRN23; Drug
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more

Conditions: Netherton Syndrome
Interventions: DS-2325a, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Tourette Syndrome, Persistent Tic Disorder
Interventions: CBIT; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 10 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: San Diego, California • Minneapolis, Minnesota

Conditions: Hyperbilirubinemia
Interventions: Not listed
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: Up to 7 Days
Enrollment: 925 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Long qt Syndrome, Torsade de Pointes
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Boston, Massachusetts • West Roxbury, Massachusetts

Search by objective public record fields.

Genome Sequencing in the Intensive Care Unit Population

A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol

Comparison of Baby Dolls for Teaching Newborn Positioning and Attachment

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

Diagnosis and Treatment of Patients With Cystic Fibrosis

Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants

Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia

Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

Glucose Homeostasis in Pseudohypoparathyroidism

Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease

Investigating Changes in Premonitory Urges During Habit Reversal Training for Tics

Training Balance Among People With Neurodevelopmental Disabilities

Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

Milk Beta Caseins on Digestive Discomfort, Gastric Emptying

Stroke With Transfusions Changing to Hydroxyurea

A Prospective, Observational Study in Patients With Late-Onset Pompe Disease

The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study

An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

Multimodal Profiling of Response to Pediatric Comprehensive Behavioral Intervention for Tics

Implementation of a Clinical Decision Rule for Treatment of Neonatal Jaundice in the Emergency Department

A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes